Skip to content

Study · Randomized controlled trial · n = 1,010 · 2003

5 results

Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.

de Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W, Sauerbrei W

Journal of clinical oncology : official journal of the American Society of Clinical Oncology10 Nov 2003Cited by 42 (Europe PMC)

PMID14610048 (opens in a new tab)DOI10.1200/jco.2003.11.064 (opens in a new tab)PepBankPUB-14610048
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with node-positive early breast cancer, overall quality-of-life change at 6 months favored goserelin over CMF (6.96 +/- 0.88 versus 0.69 +/- 0.92; P <.0001).

    In plain wordsIn women with early breast cancer, overall quality of life improved more with goserelin than CMF at 6 months.

    Peptide
    Goserelin
    Outcome
    IncreaseOverall quality of life at 6 months
    Study

    n = 1,010

    Comparator
    CMF chemotherapy
    Outcome group
    Quality of life · Whole body
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Measurements

    Overall QoL change
    6.96
    goserelin at 6 months
    Reported variability
    0.88
    goserelin
    Overall QoL change
    0.69
    CMF at 6 months
    Reported variability
    0.92
    CMF

    Source sentences

    Summary
    Significant differences were found for changes in overall QoL (eg, 6.96 +/- 0.88 v 0.69 +/- 0.92 at 6 months; P <.0001) and for physical symptom distress, activity levels, and "effort to cope with illness" dimensions.
    2 context sentences
    Summary · context
    Early benefits were noted during months 3 to 6 of treatment, for goserelin compared with CMF.
    Summary · context
    Patients from 86 centers worldwide were randomly assigned to receive either goserelin (3.6 mg every 28 days for 2 years; n = 514) or CMF (six 28-day cycles; n = 496), and were included in the QoL study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with early breast cancer, early quality-of-life benefits with goserelin versus CMF included physical distress, activity levels and effort to cope.

    In plain wordsIn women with early breast cancer, goserelin improved physical distress, activity and coping measures compared with CMF early in treatment.

    Peptide
    Goserelin
    Outcome
    Direction not reportedPhysical symptom distress, activity and effort to cope
    Study

    n = 1,010

    Comparator
    CMF chemotherapy
    Outcome group
    Quality of life · Whole body
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Significant differences were found for changes in overall QoL (eg, 6.96 +/- 0.88 v 0.69 +/- 0.92 at 6 months; P <.0001) and for physical symptom distress, activity levels, and "effort to cope with illness" dimensions.
    2 context sentences
    Summary · context
    Early benefits were noted during months 3 to 6 of treatment, for goserelin compared with CMF.
    Summary · context
    Patients from 86 centers worldwide were randomly assigned to receive either goserelin (3.6 mg every 28 days for 2 years; n = 514) or CMF (six 28-day cycles; n = 496), and were included in the QoL study.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with early breast cancer, overall and specific quality-of-life dimensions did not differ significantly between goserelin and CMF at 1, 2 and 3 years.

    In plain wordsIn women with early breast cancer, quality of life did not differ significantly between goserelin and CMF at later yearly assessments.

    Peptide
    Goserelin
    Outcome
    No significant changeOverall and specific quality of life at later assessments
    Study

    n = 1,010

    Comparator
    CMF chemotherapy
    Outcome group
    Quality of life · Whole body
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    At 1, 2, and 3 years, there were no significant differences in overall QoL or specific QoL dimensions.
    1 context sentence
    Summary · context
    Patients from 86 centers worldwide were randomly assigned to receive either goserelin (3.6 mg every 28 days for 2 years; n = 514) or CMF (six 28-day cycles; n = 496), and were included in the QoL study.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with early breast cancer, hormonal symptom scores were worse with goserelin than CMF during the 2-year goserelin treatment period.

    In plain wordsIn women with early breast cancer, hormonal symptoms were worse with goserelin than CMF during treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseHormonal symptoms during treatment
    Study

    n = 1,010

    Comparator
    CMF chemotherapy
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Scores for hormonal symptoms were worse with goserelin during the 2-year goserelin treatment period; however, this trend was reversed at 3 years.
    1 context sentence
    Summary · context
    Patients from 86 centers worldwide were randomly assigned to receive either goserelin (3.6 mg every 28 days for 2 years; n = 514) or CMF (six 28-day cycles; n = 496), and were included in the QoL study.
  5. 05HumanRandomized controlled trialSafety outcome

    In women with early breast cancer, the worse hormonal symptom trend with goserelin versus CMF during treatment reversed at 3 years.

    In plain wordsIn women with early breast cancer, the hormonal symptom trend favored goserelin over CMF at 3 years.

    Peptide
    Goserelin
    Outcome
    DecreaseHormonal symptoms at 3 years
    Study

    n = 1,010

    Comparator
    CMF chemotherapy
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Scores for hormonal symptoms were worse with goserelin during the 2-year goserelin treatment period; however, this trend was reversed at 3 years.
    1 context sentence
    Summary · context
    Patients from 86 centers worldwide were randomly assigned to receive either goserelin (3.6 mg every 28 days for 2 years; n = 514) or CMF (six 28-day cycles; n = 496), and were included in the QoL study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.